Hyperparathyroidism secondary: treatments, associated drugs and conditions

Summary:

Hyperparathyroidism secondary: an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary.

We study 29,891 people who have Hyperparathyroidism secondary. The information that eHealthMe analyzes includes:

- Medications that treat Hyperparathyroidism secondary and their effectiveness
- 697 drugs that are associated with Hyperparathyroidism secondary



Number of reports submitted per year:

Hyperparathyroidism secondary: 29,891 reports.

Hyperparathyroidism secondary treatments and how effective are they?

All the drugs that are associated with Hyperparathyroidism secondary:

Do you take any medication?

- You can use our AI-powered tools to monitor drug safety and effectiveness.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference. Browse all conditions on eHealthMe.



Recent studies on eHealthMe: